List view / Grid view
Data suggests Boehringer Ingelheim’s novel glucagon/GLP-1 receptor dual agonist could…
Data suggests Boehringer Ingelheim’s novel glucagon/GLP-1 receptor dual agonist could become a best-in-class liver disease treatment for metabolic dysfunction-associated steatohepatitis (MASH).
The first SGLT2 inhibitor to demonstrate a statistically significant reduction…
The first SGLT2 inhibitor to demonstrate a statistically significant reduction in all-cause hospitalisations in chronic kidney disease (CKD) patients versus placebo has been approved in the EU.
The data from the 12 week trial showed phosphodiesterase 4B…
The data from the 12 week trial showed phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).
